The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.
The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States, according to the New York Times. Florida estimated that it could save up to $150 million in its first year of the program, which would import drugs for treating HIV/AIDS, hepatitis C, diabetes, and psychiatric conditions. This approval represents a major US policy shift as pharmaceutical companies objected to this practice for decades, and the Pharmaceutical Research and Manufacturers of America (PhRMA), is expected to sue to prevent the plan from going into effect. Despite this, supporters hope this will be a significant step forward in reining in drug prices as other states have applied to the FDA to set up similar programs.
Health insurance companies are revamping their technology to encourage more people to get their medications through the mail, according to the Wall Street Journal. For years, insurance companies have operated their own mail-order prescription businesses, but these can be time-consuming for patients. Consequently, insurers are improving user interfaces to grow existing mail-order businesses. For example, CarelonRx, Elevance Health’s pharmacy benefits manager, rolled out a new digital pharmacy that lets users live chat with pharmacists, compare prescription costs, and arrange mail delivery for maintenance medications and refills. The company noted that it should now take fewer than 5 clicks after opening the app to order a refill and it expects the number of members ordering refills by mail to more than triple in the next few years.
A study published Tuesday reported that nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave, according to Politico. The researchers explained that hydroxychloroquine is an antimalarial drug that was prescribed to some hospitalized patients during the first wave of the pandemic despite there being no evidence of its clinical benefits. At the time, then-US President Donald Trump considered it a “miracle cure.” Overall, the researchers estimated that about 16,990 people across 6 countries, including the United States, may have died because of the drug; they noted that the total number may be far higher as the study only analyzed 6 countries.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
2 Commerce Drive
Cranbury, NJ 08512